Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 104

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 104
---
2x) |     |                     | 80 |

Leerink Partners compared this range of adjusted enterprise values to the consideration of $100 million proposed to be paid to Aadi in the Divestiture. General Leerink Partners is a full-service securities firm engaged in securities trading and brokerage activities as well as investment banking and financial advisory services. In addition to its services in connection with the Divestiture, Leerink Partners is currently serving as financial advisor to Aadi in connection with the License Agreement and will receive fees of $4,900,000 in the aggregate for such services. In the ordinary course of business, Leerink Partners may in the future provide investment banking services to Aadi, Kaken Parent or their respective affiliates and would expect to receive customary fees for the rendering of such services. In the ordinary course of its business, Leerink Partners has in the past held and may in the future hold positions, for its own account or the accounts of its customers, in equity, debt or other securities of Aadi, Kaken Parent or their respective affiliates. Consistent with applicable legal and regulatory requirements, Leerink Partners has adopted policies and procedures to establish and maintain the independence of its research department and personnel. As a result, - 67 -

Leerink Partners’ research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to Aadi, Kaken Parent and the Divestiture and
other participants in the Divestiture that differ from the views of Leerink Partners’ investment banking personnel.

Aadi selected
Leerink Partners as its financial advisor in connection with the Divestiture based on Leerink Partners’ qualifications, reputation, experience and expertise in the biopharmaceutical industry, its knowledge of and involvement in recent
transactions in the biopharmaceutical industry and its familiarity with Aadi and its business. Leerink Partners is an internationally recognized investment banking firm that has substantial experience in transactions similar to the Divestiture.

In connection with Leerink Partners’ services as financial advisor to Aadi in the Divestiture, Aadi has agreed to pay Leerink Partners an aggregate fee
of $2.75 million, $1 million of which became payable upon the rendering by Leerink Partners of its opinion on December 19, 2024, and the remainder of which is payable contingent upon consummation of the Divestiture. In addition, Aadi has
agreed to reimburse certain of Leerink Partners’ expenses arising, and to indemnify Leerink Partners against